Summary
Genetically engineered Salmonella offer an intriguing new approach to selectively target solid tumors, including melanoma, lung, colon, breast, kidney and liver. These bacteria target tumors after systemic administration and selectively replicate within them. Specificity for tumors is often more than 1,000 times greater than for any other tissue. Auxotrophic mutations make these bacteria highly safe and form the basis for maintaining tumor specificity. An altered lipid greatly reduces the potential for septic shock yet also retains the antitumor properties of these bacteria. These bacteria have innate antitumor activity towards both primary and metastatic tumors and the ability to deliver proteins capable of activating chemotherapeutic agents directly within tumors. The delay in tumor growth results in mice that survive up to twice as long. These bacteria are susceptible to a wide range of antibiotics, allowing external control of the vector after administration. The combination of these features within a single vector seems especially surprising considering their unlikely source.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Allen, T.M., Hansen, C.B., and Zalipsky, S. 1995. Antibody-targeted stealth liposomes. In: Stealth Liposomes, D.D. Lasic (ed), CRC Press, Boca Raton, pp. 233–244.
Bacon, G.A., Burrows, T.W., and Yates, M. 1950. The effects of biochemical mutation on the virulence of bacterium typhosum: The virulence of mutants. Br. J. Exp. Path.31:714–724.
Bacon G.A., Burrows T.W., and Yates M. 1951. The effects of biochemical mutation on the virulence of bacterium typhosum: The loss of virulence of certain mutants. Br. J. Exp. Path.32:85–96.
Baselga, J., Norton, L., Albanell, J., Kim, Y.-M., and Mendelsohn, J. 1998. Recombinant humanized anti-HER2 antibody (HerceptinTM) enhances the antitumor activity of paclitaxol and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res.58:2825–2831.
Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science274:373–376.
Boucher, Y., Leunig, M., and Jain, R.K. 1996. Tumor angiogenesis and interstitial hypertension. Cancer Res.56:4264–4266.
Carey, R.W., Holland, J.F., Whang, H.Y., Neter, E., and Bryant, B. 1967. Clostridial oncolysis in man. Eur. J. Cancer3:37–46.
Carter, P.B., and Collins, F.M. 1974. The route of enteric infection in normal mice. J. Exp. Med.139:1189–1203.
Fox, M.E., Lemmon, J.J., Mauchline, M.L., Davis, T.O., Giaccia, A.J., Minton, N.P., and Brown, J.M 1996. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Therapy3:173–178.
Friedman, P.N., McAndrew, S.J., Gawlak, S.L., Trail, P.A., Brown, J.P., and Siegall, C.B. 1993. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res.53:334–339.
Garapin A.C., Colbère-Garapin, F., Cohen-Solal, Horondniceanu, F., and Kourilsky, P. 1981. Expression of herpes simples virus type I thymidine kinase gene in Escherichia coli. Proc. Natl. Acad. Sci. USA78:815–819.
Gotoh, A., Ko, S.C., Shirakawa, T., Cheon, J., Kao, C., Miyamoto, T., Gardner, T.A., Ho, L.J., Cleutjens, C.B., Trapman, J., Graham, F.L., and Chung, L.W. 1998. Development of prostate-specific antigen promoterbased gene therapy for androgen-independent human prostate cancer. J. Urol.160:220–229.
Groisman, E.A., and Saier, M.H. Jr. 1990. Salmonella virulence: new clues to intramacrophage survival. Trends Biochem. Sci.15:30–33.
Hoiseth, S.K.J., and Stocker, B.A.D. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature291:238–239.
Jain, R.K. 1994. Barriers to drug delivery in solid tumors. Scientific American271(July):58–65.
Joiner, K.A. 1988. Complement evasion by bacteria and parasites. Ann. Rev. Microbiol.42:201–230.
Khan, S.A., Everest, P., Servos, S., Foxwell, N., Zähringer, U., Brade, H., Rietschel, E. Th., Dougan, G., Charles, I.G., and Maskell, D.J. 1998. A lethal role for lipid A in Salmonella infections. Mol. Mircobiol.29:571–579.
King, I., Feng, M, Luo, X., Lin, S., Bermudes, D., and Zheng, L.-M. 1998. Tumor-targeted Salmonella expressing cytosine deaminase converted 5-fluorocytosine to 5-fluorouracil and inhibited tumor growth in vivo. Proc. Amer. Asoc. Can. Res.39, p. 512, Abstract 3484.
Kops, S.K., Luo, X., Fischer, J., Le, T., Bermudes, D., Bolognia, J.L., Carmichael, E., Key-Yen, A., King, I., Low, K.B., Pawelek, J.M., Sodi. S.S., and Zheng, L.-M. Salmonella typhimurium as an anti-cancer vector: Localization within solid tumors. Proc. Amer. Asoc. Can. Res.38, p. 7, Abstract 46.
Lemmon, M.J., van Zijl, P., Fox, M.E., Mauchline, M.L., Giaccia, A.J., Minton, N.P., and Brown, J.M. 1997. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Therapy4:791–796.
Low, K.B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A., Fischer, J., Lin, S.L., Luo, X., Miller, S.I., Zheng, L.-M., King, I., Pawelek, J.M., and Bermudes, D. 1998. Disruption of the Salmonella msbB gene suppresses virulence and TNFα induction yet retain tumor-targeting in vivo. Proc. Amer. Asoc. Can. Res.39, p. 60, Abstract 409.
Möse, J.R., and Möse, G. 1964. Oncolysis by Clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res.24:212–216.
Parker, R.C., Plummer, H.C., Siebenmann, C.O., and Chapman, M.G. 1967. Effect of histollyticus infection and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med.66:461–467.
Pawelek, J., Low, K.B., and Bermudes, D. 1997. Tumor-targeted Salmonella as a novel anti-cancer vector. Cancer Research57:4537–4544.
Siegall, C.B. 1995. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. Semin Cancer Biol.6:289–295.
Trail, P.A., Willner, D., Lasch, S.J., Henderson, A.J., Hostead, S., Casazaza, A.M., Firestone, R.A., Hellström, I., and Hellström, K.E. 1993. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science261:212–215.
Zheng, L.-M., Luo, X., Fischer, J., Le, T., Bermudes, D., Low, B., Pawelek, J.M., and King, I. 1997. Attenuated Salmonella typhimurium inhibited tumor metastasis in vivo. Proc. Amer. Asoc. Can. Res.38, p. 9, Abstract 60.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Bermudes, D., Low, B., Pawelek, J. (2002). Tumor-Targeted Salmonella . In: Habib, N.A. (eds) Cancer Gene Therapy. Advances in Experimental Medicine and Biology, vol 465. Springer, New York, NY. https://doi.org/10.1007/0-306-46817-4_6
Download citation
DOI: https://doi.org/10.1007/0-306-46817-4_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-306-46191-0
Online ISBN: 978-0-306-46817-9
eBook Packages: Springer Book Archive